Teva Shares Rise After Strong Q2 Brand Growth and Higher Outlook

Teva Pharmaceutical Industries (TEVA) is up 9.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears tied to Teva’s second-quarter update, which showed stronger-than-expected revenue and a higher outlook for its three key growth brands. Investors also seem encouraged that rapid growth in AUSTEDO, AJOVY, and UZEDY is helping offset pressure from lower generic sales, especially lenalidomide.

Details:

Teva reported Q2 2026 revenue of about $4.1 billion, while its key innovative brands generated more than $1 billion combined in the quarter.

The company raised its 2026 revenue outlook for AUSTEDO, AJOVY, and UZEDY, and now expects roughly $3.7 billion of combined revenue from those products this year.

AUSTEDO revenue rose 40% year over year in local currency, AJOVY increased 56%, and UZEDY climbed 43%, showing that the higher-growth portfolio is gaining importance in the business mix.

Although reported earnings were pressured by acquisition-related charges tied to Emalex, Teva maintained its broader earnings and free-cash-flow outlook and highlighted continued pipeline progress and an investment-grade credit rating upgrade.

Sources:

Teva Investor Relations, SEC, MarketBeat

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TEVA Insider Trading Activity

$TEVA insiders have traded $TEVA stock on the open market 28 times in the past 6 months. Of those trades, 0 have been purchases and 28 have been sales.

Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:

RICHARD D FRANCIS (President and CEO) has made 0 purchases and 5 sales selling 492,506 shares for an estimated $15,938,289.
ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) has made 0 purchases and 2 sales selling 452,373 shares for an estimated $15,268,016.
RICHARD DANIELL (EVP, Europe Commercial) has made 0 purchases and 6 sales selling 237,625 shares for an estimated $7,705,163.
ERIC A HUGHES (See "Remarks") has made 0 purchases and 4 sales selling 101,572 shares for an estimated $3,281,447.
MARK SABAG (See "Remarks") sold 62,102 shares for an estimated $1,871,816
EVAN LIPPMAN (EVP, Business Development) has made 0 purchases and 2 sales selling 41,658 shares for an estimated $1,482,366.
MATTHEW SHIELDS (EVP, Global Operations) has made 0 purchases and 3 sales selling 43,479 shares for an estimated $1,401,581.
CHRISTINE FOX (EVP, U.S. Commercial) has made 0 purchases and 2 sales selling 17,022 shares for an estimated $546,302.
PLACID JOVER (See "Remarks") sold 14,150 shares for an estimated $448,107
BRIAN SAVAGE (Interim Chief Legal Officer) has made 0 purchases and 2 sales selling 2,401 shares for an estimated $76,916.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive TEVA Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$TEVA Hedge Fund Activity

We have seen 316 institutional investors add shares of $TEVA stock to their portfolio, and 233 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

WCM INVESTMENT MANAGEMENT, LLC added 26,813,522 shares (+191.4%) to their portfolio in Q1 2026, for an estimated $807,623,282
GLENVIEW CAPITAL MANAGEMENT, LLC removed 10,032,460 shares (-60.1%) from their portfolio in Q1 2026, for an estimated $302,177,695
MEITAV INVESTMENT HOUSE LTD added 9,947,045 shares (+inf%) to their portfolio in Q2 2026, for an estimated $337,005,884
BLACKROCK, INC. added 6,833,776 shares (+11.7%) to their portfolio in Q1 2026, for an estimated $205,833,333
CAPITAL WORLD INVESTORS added 6,472,554 shares (+274.1%) to their portfolio in Q1 2026, for an estimated $194,953,326
RUBRIC CAPITAL MANAGEMENT LP removed 6,105,510 shares (-28.6%) from their portfolio in Q1 2026, for an estimated $183,897,961
FMR LLC added 4,117,813 shares (+14.2%) to their portfolio in Q1 2026, for an estimated $124,028,527

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TEVA Congressional Stock Trading

Members of Congress have traded $TEVA stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $TEVA stock by members of Congress over the last 6 months:

SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$TEVA Analyst Ratings

Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Truist Securities issued a "Buy" rating on 04/30/2026

To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative's $TEVA forecast page.

$TEVA Price Targets

Multiple analysts have issued price targets for $TEVA recently. We have seen 7 analysts offer price targets for $TEVA in the last 6 months, with a median target of $42.0.

Here are some recent targets:

Glen Santangelo from Barclays set a target price of $40.0 on 05/06/2026
Les Sulewski from Truist Securities set a target price of $45.0 on 04/30/2026
David Amsellem from Piper Sandler set a target price of $42.0 on 04/30/2026
Ashwani Verma from UBS set a target price of $42.0 on 04/30/2026
Chris Schott from JP Morgan set a target price of $40.0 on 04/30/2026
Jason Gerberry from B of A Securities set a target price of $42.0 on 04/09/2026
Matt Dellatorre from Goldman Sachs set a target price of $45.0 on 02/09/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.